Autoantibodies targeting the protein RGS8 (regulator of G-protein signaling 8) are associated with a particular subtype of Hodgkin’s lymphoma, as described in a recently published study performed in a collaboration between EUROIMMUN and research institutes in France, Spain and USA. The novel autoantibodies are suggested to be of at least intermediate risk for paraneoplastic neurological […]
EUROIMMUN chemiluminescence immunoassays (ChLIA) for Alzheimer’s disease (AD) biomarkers provide reliable analytical and clinical performance, as demonstrated in two newly published studies performed in a collaboration between researchers at EUROIMMUN and the Memory Clinic of the University Hospital Magdeburg, Germany. Measurement of the four core biomarkers beta-amyloid (Aβ) 1-40, Aβ1-42, total tau and tau phosphorylated
A novel cell-based immunofluorescence assay (CBA) provides sensitive and specific detection of IgM antibodies against myelin-associated glycoprotein (MAG), as demonstrated in a study published in collaboration with scientists from the University of Verona and the Pediatric Research Institute in Padua, Italy. The Anti-MAG CBA is now available for research use*. Anti-MAG-IgM antibodies are markers for
There is a huge variety of neurological diseases and it often takes specialists a long time to figure out the cause of a patient’s symptoms. Doctors regularly encounter patients with unspecific neurological complaints. In these cases, differential diagnostics is crucial to finding the right therapy. Even if the doctor has a suspicion and there are
Diacylglycerol lipase alpha (DAGLA) has been identified as a novel autoantibody target in patients with rapid progressive cerebellar ataxia. The autoantibodies were characterised as part of a collaborative study between scientists at EUROIMMUN (Lübeck, Germany), the Hannover Medical School, (Hannover, Germany) and further institutes and clinics. The study was published in April 2024 the journal
